Stocksigma LogoStocksigma Logo

Accretion Pharmaceuticals Exempt From Q2 FY27 Corporate Governance Reporting

Accretion Pharmaceuticals Limited confirmed the non-applicability of Regulation 27(2) of SEBI LODR Regulations, 2015, regarding the submission of quarterly

Accretion Pharmaceuticals Exempt From Q2 FY27 Corporate Governance Reporting

Accretion Pharmaceuticals Ltd 路 Others (Uncategorized) 路 10 Oct 2026, 9:17 pm

Accretion Pharmaceuticals Exempt From Q2 FY27 Corporate Governance Reporting Accretion Pharmaceuticals Limited confirmed the non-applicability of Regulation 27(2) of SEBI LODR Regulations, 2015, regarding the submission of quarterly Corporate Governance compliance reports for the quarter ended 30th Sep'26 (Q2 FY27). Under Regulation 15(2)(b), entities with securities listed on the SME Exchange (NSE Emerge Platform) are exempt from these governance provisions. The filing is supported by a certification from practicing company secretary firm M/s Sakhiya & Co., dated 9th Oct'26, confirming the regulatory exemption.

Original exchange filing (PDF)

More announcements from Accretion Pharmaceuticals Ltd

All Accretion Pharmaceuticals Ltd announcements